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Antibody blockade of immune checkpoint regulators
such as PD-1 and CTLA4 has been shown to be an
effective cancer treatment strategy; however, a large per-
centage of patients still do not respond to existing
therapies. Discovery of additional immune checkpoints
and development of antibody therapeutics against them
are likely critical to address this unmet patient need.
We generated a comprehensive library of essentially all
human extracellular proteins and screened proteins in
this library in vitro and in vivo for the ability to modu-
late immune responses or tumor growth. As a result of
these screens, we identified a number of novel immune
checkpoints1.
One such protein, referred to herein as Novel Check-
point 1, was originally identified through its inhibitory
activity on anti-CD3-stimulated human T cell prolifera-
tion. To confirm its activity as an immune checkpoint,
we demonstrated that the native protein expressed on an
antigen-presenting cell line could inhibit antigen-stimu-
lated CD8+ T cell activation. Furthermore, blocking anti-
bodies against this protein relieved the inhibition. This
inhibitory activity translated to a murine system, as the
mouse ortholog and blocking antibodies behaved simi-
larly in murine T cell activation assays. Overexpression
of the protein in mouse syngeneic tumor models resulted
in increased tumor growth, consistent with inhibition of
anti-tumor immune responses. Novel Checkpoint 1 is
expressed primarily on activated and regulatory T cells in
humans and mice – an expression profile similar to those
of PD-1 and CTLA4. Additionally, it is expressed on
40-70% of tumor-infiltrating T cells while only on 10-
15% of circulating T cells from those tumor-bearing
mice. We are currently evaluating the anti-tumor activity
of blocking antibodies in mouse tumor models, either
alone or in combination with other checkpoint blocking
antibodies. Taken together, we believe that these data
demonstrate that this newly discovered protein may act
as a checkpoint regulator in tumors and that blocking
antibodies against it have potential as a novel cancer
immunotherapeutic.
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